Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03592277 · ClinicalTrials.gov registry record · Phase 2
Vitamin C & Thiamine to Treat Sepsis and Septic Shock
A Phase 2 study, sponsored by Trinity Health Of New England.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT03592277 is a Phase 2 study that has completed, run by Trinity Health Of New England. The registered enrollment target is 120 participants.
The verdict
NCT03592277, a Phase 2 study, has completed, sponsored by Trinity Health Of New England.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
Investigators propose to investigate the use of IV vitamins B1 and C in a randomized, double-blinded, prospective trial to determine if these medications decrease mortality rates in patients with severe sepsis or septic shock.
Interventions
- DRUG Vitamin C
- DRUG Vitamin B1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2018-09-14 |
| Est. Completion | 2021-02-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03592277
The ClinicalTrials.gov registry entry for NCT03592277 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trinity Health Of New England, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vitamin C is the first listed.
NCT03592277 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03592277 about?
NCT03592277 is a clinical study titled "Vitamin C & Thiamine to Treat Sepsis and Septic Shock". Investigators propose to investigate the use of IV vitamins B1 and C in a randomized, double-blinded, prospective trial to determine if these medications decrease mortality rates in patients with severe sepsis or septic shock.
What is the current status of trial NCT03592277?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2018-09-14. Estimated completion is 2021-02-22.
What interventions are being tested in trial NCT03592277?
The interventions under investigation include: Vitamin C (DRUG), Vitamin B1 (DRUG).
Who is sponsoring clinical trial NCT03592277?
This trial is sponsored by Trinity Health Of New England, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.